NEU
NEUREN FPO NZ [NEU]
Healthcare · ASX Small Cap
$13.9600 +7.0%
Updated 2026-03-02 · Scores refresh every scan
Appeared in 2 consecutive scans→ Score +6First seen: 2026-02-25
Score Breakdown
Technical70
Catalyst52
Sentiment50
Fundamental60
Momentum48
Risk Gate33
Active Signals
Bullish Signals
- MACD momentum strengthening
- Bollinger squeeze (breakout building)
- Strong 5-day momentum (+14.1%)
- Volatility contracting (breakout setup)
- Cash positive / operating cashflow positive
- Revenue in sharp decline (-75%)
- Piotroski F-Score strong (7/9)
- EPS estimates revised upward (+10pts)
- Elevated short interest (5.5%)
- Earnings in sharp decline (-88% QoQ)
- CANSLIM A: Turned profitable
- CANSLIM I: Institutional ownership (23%)
- Healthy profit margins (40%)
- Positive 12-1 momentum (+20%)
- Analyst EPS expectations rising (+127%)
- Altman Z-Score in grey zone (2.28)
- Days to cover very high (12.7)
- ASX200 bullish (+1.5% 5d)
- RBA cutting (+2pts)
- Trial readout: PHASE2 (est. 2014-09)
Risk Signals
- Below 200-day MA (long-term downtrend)
- Post-earnings drift: negative surprise (SUE -10)
- Insufficient sentiment data (defaulting to neutral)
- Neutral/mixed sentiment
- Earnings momentum negative
- Revenue momentum declining (-75%)
Recent Catalysts
LOW Investor presentation, 27 February 2026
NONE 2025 royalty income A$65m, profit after tax A$30m
NONE Appendix 4E and 2025 full year accounts
NONE Acadia reports DAYBUE net sales for 2025 and 2026 guidance
Recent ASX Announcements
| 2026-02-27 | Investor presentation, 27 February 2026 |
| 2026-02-26 | 2025 royalty income A$65m, profit after tax A$30m PRICE SENSITIVE |
| 2026-02-26 | Appendix 4E and 2025 full year accounts PRICE SENSITIVE |
| 2026-02-26 | Acadia reports DAYBUE net sales for 2025 and 2026 guidance PRICE SENSITIVE |
| 2026-02-25 | Pause in Trading PRICE SENSITIVE |
Key Metrics
$1.8B
Market Cap
554K
Avg Volume
1.2x
Vol Ratio
$8.61 — $22.98
52-Week Range
5.5%
Short Interest
N/A
Cash Runway
8.7%
ROE
39.6%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: -88% |
| A | Annual Earnings | improving | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 88% |
| L | Leader vs Laggard | laggard | RS: -6 |
| I | Institutional Sponsorship | pass | Inst: 22% |
| M | Market Direction | pass | Bullish |
Sector: Healthcare
Ranked #3 of 119 · Sector avg: 51
View all Healthcare signals →